ZVRA: High Short Interest Meets a Bullish Street, With Earnings 32 Days Out
Zevra Therapeutics heads into its November 9 earnings report with a notable gap between what short sellers are betting and what analysts are saying. Short interest is genuinely elevated at 10.4% of the free float,…